C5 and meningococcal infection: Since eculizumab prevents the terminal complement pathway through inhibition of C5 cleavage, and Neisseria meningitidis is primarily eliminated by the terminal complement components, patients treated with eculizumab are at increased risk of meningococcal infections [18].